GlassScriptPhysician profile
Laurence A Primack
NPI 1689605586
$4,304.34
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,298 · 2020: $966 · 2021: $993 · 2022: $20.12 · 2023: $27.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $343.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $327.35 | 2019-2021 | |
| Ucb, INC. | $326.21 | 2019-2023 | Briviact |
| Neurocrine Biosciences, INC. | $299.42 | 2019-2021 | |
| Greenwich Biosciences, INC. | $240.21 | 2019-2021 | |
| Emd Serono, INC. | $233.60 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $229.62 | 2019-2021 | |
| Biogen, INC. | $228.33 | 2019-2021 | |
| Lilly USA, LLC | $187.13 | 2019-2021 | |
| Amgen INC. | $178.88 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $175.80 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $156.05 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $152.13 | 2019-2021 | |
| Acorda Therapeutics, INC | $143.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $130.62 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $113.14 | 2020-2021 | |
| Tanabe Pharma America, INC. | $99.32 | 2019-2021 | |
| Lundbeck LLC | $93.77 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $70.26 | 2019-2020 | |
| Sk Life Science, INC. | $65.24 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $60.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.14 | 2020-2021 | |
| Celgene Corporation | $52.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.06 | 2020-2021 | |
| Abbvie INC. | $52.04 | 2021 | |
| Pfizer INC. | $48.49 | 2019 | |
| Csl Behring | $45.96 | 2019 | |
| Genentech USA, INC. | $36.56 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $32.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.53 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.73 | 2021 | |
| Neurelis, INC. | $15.29 | 2020 | |
| Allergan, INC. | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Primack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.